In another case report, the survival of patients with SCLC harboring an EML4-ALK fusion mutation was significantly improved after first-line treatment with crizotinib, demonstrating the potential of crizotinib for the treatment of SCLC accompanied by ALK fusion and further validating the potential of targeting the ALK gene mutation in such rare circumstances [13]. Here, EML4 is linked to small cell lung carcinoma.